

Continuation Investments Limited

5 May 2015

Manager of Company Announcements
ASX Limited
Level 8, Exchange Plaza
2 The Esplanade
PERTH WA 6000

By E-Lodgement

Company Update

Continuation Investments Ltd (ASX:COT) provides the following company update:

- In recent months as part of its overall and continuing investment strategy, COT has assessed numerous listed equities investment opportunities across various securities exchanges globally. These opportunities have predominantly been in the growth company sector for companies with a market capitalisation of sub-\$100m. COT has participated in equity placements and completed on-market purchases and sales of listed equities. The Company continues to review opportunities and will transact on those to the extent that the investment review yields a sufficiently attractive risk-reward proposition.
- COT is also reviewing various unlisted investment opportunities with a focus on higher yielding debt or hybrid instruments. It currently holds an 8% US\$300,000 promissory note investment into The Biofusionary Company, Inc. -- a Denver based medical technology company with an FDA approved electromagnetic tissue tightening device. Principal and interest is being paid monthly. In addition, COT recently invested into Hong Kong based fine jewellery purveyor, Plukka, by way of a 12% A\$500,000 loan note instrument. For more information on Plukka, please refer to their website www.plukka.com.
- COT continues to discuss with unrelated parties the potential to significantly capitalise its balance sheet in order to aggressively pursue a strategy of focusing on investing in growth companies globally. While such discussions are ad-hoc and preliminary, the Board has resolved to seek shareholder pre-approval to conduct a placement of up to \$3m in order that, should the opportunity arise, the Company is enabled to move swiftly. A Notice of Meeting has been despatched to shareholders seeking such approval.

For and on behalf of the Board



Jeremy King
Chairman